Reduced Anticoagulant Effect of Dabigatran in a Patient Receiving Concomitant Phenytoin Objective — Interaction of dabigatran with phenytoin in a patient with Cerebral venous thrombosis Introduction Dabigatran, a direct…
Background: The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism. Dabigatran was proven…
complications. Various platforms of laboratory assay are available for measuring the drug level of dabigatran, rivaroxaban and apixaban. The measurement of rivaroxaban and apixaban can be done by anti ... assay and…
Objectives To provide early data regarding clinical utility of Dabigatran in Al Ain Hospital, United Arab Emirates (UAE). Methods This was an ethics approved retrospective cross sectional study. We retrieved ... total…
Dabigatran, a reversible direct thrombin inhibitor, is a new oral anticoagulant developed for long-term prevention of thromboembolic disorders whose safety profile is not completely known yet. Here we report…
other blood coagulation disorders until recently the non-vitamin K antagonist, dabigatran came about as another option for prevention of stroke in patients with non-valvular atrial fibrillation ... questioning with…
factors for bleeding over various renal function ranges in patients on enoxaparin, fondaparinux, or dabigatran. Methods: Retrospective chart review from 2010 until 2011 identified patients who incurred a bleeding…
stability indicating, highly accurate precise and linear method for related substance of the Dabigatran through the reverse phase high performance liquid chromatography and it is validated as per the current…
Dabigatran has been used recently as an alternative to warfarin therapy for the prevention of thromboembolism in patients with myocardial infarction or atrial fibrillation, but treatment of established intracardiac…
present invention describes the improved process for the preparation of dabigatran etexilate mesylate and impurities synthesis. The Synthesis involves easily available commercial raw materials with Acylation from…
Dabigatran etexilate is a direct thrombin inhibitor that offers potential advantages over existing anticoagulants for the prevention and treatment of venous and arterial thrombosis. It is administered orally…
patients with nonvalvular atrial fibrillation, dabigatran etexilate is a new oral direct thrombin inhibitor to prevent stroke and systemic embolization. Dabigatran has few drug or food interactions, and has predictable…
drugs with steep exposure-response relationships exhibiting high pharmacokinetic (PK) variability such as dabigatran represent an expensive challenge for pharmaceutical companies. Supported by the population…
Introduction: Dabigatran, a direct thrombin inhibitor, is an oral novel anticoagulant, which is used in stroke prophylaxis in non valvular atrial fibrillation. Despite it’s many benefits in use, lack ... weeks apart, on…
Objective: To evaluate the effectiveness of dabigatran etexilate in patients with atrial fibrillation who underwent operative treatment at the ICA. Materials and Methods: From Sept ... patients with atrial fibrillation…
validated, simple, precise, stability indicating reverse phase HPLC method for the determination of Dabigatran etexilate mesylate in bulk drug and dosage form. LC separationwas achieved gradientmode on a Zorbax…
method has been developed and validated for the determination for eight related substances of Dabigatran Etexilate Mesylate. The successful chromatographic separation of Dabigatran Etexilate from its related substances…
effective for rapid, durable, and safe reversal of the anticoagulant effect of dabigatran. We will describe herein the third case reported so far on the use of idarucizumab ... patient on dabigatran for nonvalvular…
performed a single-center, retrospective cohort study of 98 cases of DOAC therapy (apixaban, dabigatran, or rivaroxaban) in a Veteran population with AF aged > 75 years. Baseline characteristics and comorbidities…
patients presenting with intracerebral hemorrhage secondary to CVST from occlusion of dural venous sinuses. Dabigatran, a DTI was used as the primary treatment modality for a period of 6 months
speed, high resolution Reverse phase-HPLC method was developed for estimation of assay in Dabigatran etexilate mesylate drug substance. The separation of drug from the possible impurities was achieved
further exacerbation in the progression of colon cancer. We evaluated the effect of dabigatran etexilate (DE), an oral direct thrombin inhibitor in a preclinical model of 1, 2-Dimethylhydrazine
aims of this study to develop a method and validated it for Dabigatran etexilate which is used as an anticoagulant agent. Here we reported sensitive, precise, an accurate and time
visible region has been developed and validated for quantification of metaxalone (MET) and dabigatran etexilate mesylate (DAB) in their bulk and pharmaceutical dosage forms. Methods: The method is based
Dabigatran etexilate is a new oral non-peptidic direct thrombin inhibitor approved by the FDA and EMA for stroke prevention in patients with non-valvular atrial fibrillation. Unlike warfarin, there
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.